Binding Site Information of Target
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T82393 | Target Info | |||
| Target Name | TNF alpha converting enzyme (ADAM17) | ||||
| Synonyms | TNFalpha converting enzyme; TNF-alpha-converting enzyme; TNF-alpha converting enzyme; TNF-alpha convertase; TACE; Snake venom-like protease; Disintegrin and metalloproteinase domain-containing protein 17; CSVP; CD156b antigen; CD156b; ADAM 17; A disintegrin and metalloproteinase domain 17 | ||||
| Target Type | Clinical trial Target | ||||
| Gene Name | ADAM17 | ||||
| Biochemical Class | Peptidase | ||||
| UniProt ID | |||||
| Drug Binding Sites of Target | Top | |||||
|---|---|---|---|---|---|---|
| Ligand Name: IK-862 | Ligand Info | |||||
| Structure Description | Crystal structure of TACE in complex with IK682 | PDB:2FV5 | ||||
| Method | X-ray diffraction | Resolution | 2.10 Å | Mutation | Yes | [1] |
| PDB Sequence |
ADPDPMKNTC
225 KLLVVADHRF235 YRYMGRGEES245 TTTNYLIELI255 DRVDDIYRNT265 AWDNAGFKGY 275 GIQIEQIRIL285 KSPQEVKPGE295 KHYNMAKSYP305 NEEKDAWDVK315 MLLEQFSFDI 325 AEEASKVCLA335 HLFTYQDFDM345 GTLGLAYGGS355 PRANSHGGVC365 PKAYYSPVGK 375 KNIYLNSGLT385 STKNYGKTIL395 TKEADLVTTH405 ELGHNFGAEH415 DPDGLAECAP 425 NEDQGGKYVM435 YPIAVSGDHE445 NNKMFSQCSK455 QSIYKTIESK465 AQECFQERSN 475 A
|
|||||
|
|
GLY346
3.437
THR347
3.206
LEU348
2.632
GLY349
2.886
LEU350
3.793
ALA351
4.575
GLU398
3.505
LEU401
3.257
VAL402
4.100
HIS405
3.040
GLU406
2.527
HIS409
3.007
|
|||||
| Ligand Name: N-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}-5-methyl-D-tryptophan | Ligand Info | |||||
| Structure Description | Crystal Structure of TACE with Tryptophan Sulfonamide Derivative Inhibitor | PDB:3G42 | ||||
| Method | X-ray diffraction | Resolution | 2.10 Å | Mutation | Yes | [2] |
| PDB Sequence |
MKNTCKLLVV
230 ADHRFYRYMG240 RGEESTTTNY250 LIELIDRVDD260 IYRNTAWDNA270 GFKGYGIQIE 280 QIRILKSPQE290 VKPGEKHYNM300 AKSYPNEEKD310 AWDVKMLLEQ320 FSFDIAEEAS 330 KVCLAHLFTY340 QDFDMGTLGL350 AYVGSPRANS360 HGGVCPKAYY370 SPVGKKNIYL 380 NSGLTSTKNY390 GKTILTKEAD400 LVTTHELGHN410 FGAEHDPDGL420 AECAPNEDQG 430 GKYVMYPIAV440 SGDHENNKMF450 SQCSKQSIYK460 TIESKAQECF470 QERS |
|||||
|
|
GLY346
4.046
THR347
3.226
LEU348
2.777
GLY349
3.213
LEU350
3.910
ALA351
3.975
VAL353
3.692
GLU398
3.989
LEU401
3.701
VAL402
3.913
|
|||||
| Ligand Name: (1r,2s)-N~2~-Hydroxy-1-{4-[(2-Phenylquinolin-4-Yl)methoxy]benzyl}cyclopropane-1,2-Dicarboxamide | Ligand Info | |||||
| Structure Description | Crystal structure of catalytic domain of TACE with hydroxamate inhibitor | PDB:3E8R | ||||
| Method | X-ray diffraction | Resolution | 1.90 Å | Mutation | Yes | [3] |
| PDB Sequence |
PDPMKNTCKL
227 LVVADHRFYR237 YMGRGEESTT247 TNYLIELIDR257 VDDIYRNTAW267 DNAGFKGYGI 277 QIEQIRILKS287 PQEVKPGEKH297 YNMAKSYPNE307 EKDAWDVKML317 LEQFSFDIAE 327 EASKVCLAHL337 FTYQDFDMGT347 LGLAYGGSPH361 GGVCPKAYYS371 PVGKKNIYLN 381 SGLTSTKNYG391 KTILTKEADL401 VTTHELGHNF411 GAEHDPDGLA421 ECAPNEDQGG 431 KYVMYPIAGD443 HENNKMFSQC453 SKQSIYKTIE463 SKAQECFQER473 S |
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .615 or .6152 or .6153 or :3615;style chemicals stick;color identity;select .A:346 or .A:347 or .A:348 or .A:349 or .A:350 or .A:351 or .A:394 or .A:398 or .A:401 or .A:402 or .A:405 or .A:406 or .A:409 or .A:415 or .A:432 or .A:433 or .A:434 or .A:436 or .A:437 or .A:438 or .A:439 or .A:442 or .A:447; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
GLY346
3.395
THR347
2.939
LEU348
2.426
GLY349
3.030
LEU350
3.958
ALA351
4.665
ILE394
4.658
GLU398
3.405
LEU401
3.376
VAL402
3.844
HIS405
2.839
GLU406
2.370
|
|||||
| Ligand Name: 4-({4-[(4-Aminobut-2-ynyl)oxy]phenyl}sulfonyl)-N-hydroxy-2,2-dimethylthiomorpholine-3-carboxamide | Ligand Info | |||||
| Structure Description | Crystal structure of catalytic domain of TACE with Thiomorpholine Sulfonamide Hydroxamate inhibitor | PDB:2A8H | ||||
| Method | X-ray diffraction | Resolution | 2.30 Å | Mutation | Yes | [4] |
| PDB Sequence |
DPDPMKNTCK
226 LLVVADHRFY236 RYMGRGEEST246 TTNYLIELID256 RVDDIYRNTA266 WDNAGFKGYG 276 IQIEQIRILK286 SPQEVKPGEK296 HYNMAKSYPN306 EEKDAWDVKM316 LLEQFSFDIA 326 EEASKVCLAH336 LFTYQDFDMG346 TLGLAYVGSP356 RANSHGGVCP366 KAYYSPVGKK 376 NIYLNSGLTS386 TKNYGKTILT396 KEADLVTTHE406 LGHNFGAEHD416 PDGLAECAPN 426 EDQGGKYVMY436 PIAVSGDHEN446 NKMFSQCSKQ456 SIYKTIESKA466 QECFQERSN |
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .4NH or .4NH2 or .4NH3 or :34NH;style chemicals stick;color identity;select .A:346 or .A:347 or .A:348 or .A:349 or .A:350 or .A:351 or .A:398 or .A:401 or .A:402 or .A:405 or .A:406 or .A:409 or .A:415 or .A:434 or .A:436 or .A:437 or .A:438 or .A:439 or .A:440 or .A:441; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
GLY346
3.784
THR347
3.092
LEU348
2.687
GLY349
3.194
LEU350
3.332
ALA351
4.852
GLU398
3.027
LEU401
3.633
VAL402
3.838
HIS405
3.062
|
|||||
| Ligand Name: (5R)-5-[(5-methoxy-3-oxo-1,3-dihydro-2H-indazol-2-yl)methyl]-5-methylimidazolidine-2,4-dione | Ligand Info | |||||
| Structure Description | Crystal structure of catalytic domain of TACE with the first hydantoin inhibitor occupying the S1' pocket | PDB:3L0V | ||||
| Method | X-ray diffraction | Resolution | 1.75 Å | Mutation | Yes | [5] |
| PDB Sequence |
ADPDPMKNTC
225 KLLVVADHRF235 YRYMGRGEES245 TTTNYLIELI255 DRVDDIYRNT265 AWDNAGFKGY 275 GIQIEQIRIL285 KSPQEVKPGE295 KHYNMAKSYP305 NEEKDAWDVK315 MLLEQFSFDI 325 AEEASKVCLA335 HLFTYQDFDM345 GTLGLAYGGS355 PHGGVCPKAY369 YSPVGKKNIY 379 LNSGLTSTKN389 YGKTILTKEA399 DLVTTHELGH409 NFGAEHDPDG419 LAECAPNEDQ 429 GGKYVMYPIA439 VSGDHENNKM449 FSQCSKQSIY459 KTIESKAQEC469 FQERS |
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .724 or .7242 or .7243 or :3724;style chemicals stick;color identity;select .A:346 or .A:347 or .A:348 or .A:349 or .A:350 or .A:351 or .A:398 or .A:401 or .A:402 or .A:405 or .A:406 or .A:409 or .A:415 or .A:434 or .A:436 or .A:437 or .A:438 or .A:439 or .A:440; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| Ligand Name: (5r)-5-[(5-Methoxy-3-Oxo-1,3-Dihydro-2h-Indazol-2-Yl)methyl]-5-Phenylimidazolidine-2,4-Dione | Ligand Info | |||||
| Structure Description | Crystal structure of the catalytic domain of TACE with Indazolinone-phenyl-hydantoin inhibitor | PDB:3LE9 | ||||
| Method | X-ray diffraction | Resolution | 1.85 Å | Mutation | Yes | [6] |
| PDB Sequence |
PDPMKNTCKL
227 LVVADHRFYR237 YMGRGEESTT247 TNYLIELIDR257 VDDIYRNTAW267 DNAGFKGYGI 277 QIEQIRILKS287 PQEVKPGEKH297 YNMAKSYPNE307 EKDAWDVKML317 LEQFSFDIAE 327 EASKVCLAHL337 FTYQDFDMGT347 LGLAYGGHGG363 VCPKAYYSPV373 GKKNIYLNSG 383 LTSTKNYGKT393 ILTKEADLVT403 THELGHNFGA413 EHDPDGLAEC423 APNEDQGGKY 433 VMYPIAVSGD443 HENNKMFSQC453 SKQSIYKTIE463 SKAQECFQER473 S |
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .727 or .7272 or .7273 or :3727;style chemicals stick;color identity;select .A:314 or .A:315 or .A:346 or .A:347 or .A:348 or .A:349 or .A:350 or .A:351 or .A:401 or .A:402 or .A:405 or .A:406 or .A:409 or .A:415 or .A:434 or .A:436 or .A:437 or .A:438 or .A:439 or .A:440; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
VAL314
3.828
LYS315
3.646
GLY346
4.793
THR347
3.631
LEU348
2.708
GLY349
2.798
LEU350
3.738
ALA351
4.770
LEU401
3.234
VAL402
3.336
|
|||||
| Ligand Name: (2r,3r)-4-[(2r)-2-(3-Chlorophenyl)pyrrolidin-1-Yl]-2,3-Dihydroxy-4-Oxo-N-[(5-{[2-(Trifluoromethyl)-1h-Benzimidazol-1-Yl]methyl}thiophen-2-Yl)methyl]butanamide | Ligand Info | |||||
| Structure Description | Crystal structure of catalytic domain of tace with benzimidazolyl-thienyl-tartrate based inhibitor | PDB:3LGP | ||||
| Method | X-ray diffraction | Resolution | 1.90 Å | Mutation | Yes | [7] |
| PDB Sequence |
PDPMKNTCKL
227 LVVADHRFYR237 YMGRGEESTT247 TNYLIELIDR257 VDDIYRNTAW267 DNAGFKGYGI 277 QIEQIRILKS287 PQEVKPGEKH297 YNMAKSYPNE307 EKDAWDVKML317 LEQFSFDIAE 327 EASKVCLAHL337 FTYQDFDMGT347 LGLAYGGHGG363 VCPKAYYSPV373 GKKNIYLNSG 383 LTSTKNYGKT393 ILTKEADLVT403 THELGHNFGA413 EHDPDGLAEC423 APNEDQGGKY 433 VMYPIAVSGD443 HENNKMFSQC453 SKQSIYKTIE463 SKAQECFQER473 S |
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .50X or .50X2 or .50X3 or :350X;style chemicals stick;color identity;select .A:314 or .A:347 or .A:348 or .A:349 or .A:350 or .A:351 or .A:398 or .A:401 or .A:402 or .A:405 or .A:406 or .A:409 or .A:415 or .A:432 or .A:433 or .A:434 or .A:436 or .A:437 or .A:438 or .A:439 or .A:440 or .A:441 or .A:442 or .A:447; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
VAL314
4.075
THR347
3.648
LEU348
3.335
GLY349
3.184
LEU350
3.407
ALA351
4.993
GLU398
3.292
LEU401
3.401
VAL402
3.771
HIS405
3.066
GLU406
2.668
HIS409
3.286
|
|||||
| Ligand Name: (5R)-5-[(6-methoxy-1-oxoisoindol-2-ium-2-yl)methyl]-5-(4-pyridin-3-ylphenyl)imidazolidine-2,4-dione | Ligand Info | |||||
| Structure Description | Crystal structure of the catalytic domain of TACE with Isoindolinone-biphenyl-hydantoin inhibitor | PDB:3LEA | ||||
| Method | X-ray diffraction | Resolution | 2.00 Å | Mutation | Yes | [6] |
| PDB Sequence |
DPDPMKNTCK
226 LLVVADHRFY236 RYMGRGEEST246 TTNYLIELID256 RVDDIYRNTA266 WDNAGFKGYG 276 IQIEQIRILK286 SPQEVKPGEK296 HYNMAKSYPN306 EEKDAWDVKM316 LLEQFSFDIA 326 EEASKVCLAH336 LFTYQDFDMG346 TLGLAYGGSP356 RANSHGGVCP366 KAYYSPVGKK 376 NIYLNSGLTS386 TKNYGKTILT396 KEADLVTTHE406 LGHNFGAEHD416 PDGLAECAPN 426 EDQGGKYVMY436 PIAVSGDHEN446 NKMFSQCSKQ456 SIYKTIESKA466 QECFQERS |
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .Z93 or .Z932 or .Z933 or :3Z93;style chemicals stick;color identity;select .A:313 or .A:314 or .A:315 or .A:346 or .A:347 or .A:348 or .A:349 or .A:350 or .A:351 or .A:401 or .A:402 or .A:405 or .A:406 or .A:409 or .A:415 or .A:434 or .A:436 or .A:437 or .A:438 or .A:439 or .A:440; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
ASP313
4.768
VAL314
3.953
LYS315
3.605
GLY346
4.589
THR347
3.249
LEU348
2.704
GLY349
2.876
LEU350
3.485
ALA351
4.839
LEU401
3.319
VAL402
3.387
|
|||||
| Ligand Name: (3s)-1-{[4-(But-2-Yn-1-Yloxy)phenyl]sulfonyl}pyrrolidine-3-Thiol | Ligand Info | |||||
| Structure Description | Crystal structure analysis 0f the TNF-a Coverting Enzyme (TACE) in complexed with Aryl-sulfonamide | PDB:2OI0 | ||||
| Method | X-ray diffraction | Resolution | 2.00 Å | Mutation | Yes | [8] |
| PDB Sequence |
ADPDPMKNTC
225 KLLVVADHRF235 YRYMGRGEES245 TTTNYLIELI255 DRVDDIYRNT265 AWDNAGFKGY 275 GIQIEQIRIL285 KSPQEVKPGE295 KHYNMAKSYP305 NEEKDAWDVK315 MLLEQFSFDI 325 AEEASKVCLA335 HLFTYQDFDM345 GTLGLAYVGS355 PRANSHGGVC365 PKAYYSPVGK 375 KNIYLNSGLT385 STKNYGKTIL395 TKEADLVTTH405 ELGHNFGAEH415 DPDGLAECAP 425 NEDQGGKYVM435 YPIAVSGDHE445 NNKMFSQCSK455 QSIYKTIESK465 AQECFQERSN 475 KVIEGR
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .283 or .2832 or .2833 or :3283;style chemicals stick;color identity;select .A:346 or .A:347 or .A:348 or .A:349 or .A:350 or .A:351 or .A:398 or .A:401 or .A:402 or .A:405 or .A:406 or .A:409 or .A:415 or .A:434 or .A:436 or .A:437 or .A:438 or .A:439; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| Ligand Name: (3S)-4-{[4-(But-2-ynyloxy)phenyl]sulfonyl}-N-hydroxy-2,2-dimethylthiomorpholine-3-carboxamide | Ligand Info | |||||
| Structure Description | Crystal structure of catalytic domain of TNF-alpha converting enzyme (TACE) with inhibitor | PDB:1ZXC | ||||
| Method | X-ray diffraction | Resolution | 2.28 Å | Mutation | Yes | [9] |
| PDB Sequence |
DPDPMKNTCK
226 LLVVADHRFY236 RYMGRGEEST246 TTNYLIELID256 RVDDIYRNTA266 WDNAGFKGYG 276 IQIEQIRILK286 SPQEVKPGEK296 HYNMAKSYPN306 EEKDAWDVKM316 LLEQFSFDIA 326 EEASKVCLAH336 LFTYQDFDMG346 TLGLAYVGSP356 RANSHGGVCP366 KAYYSPVGKK 376 NIYLNSGLTS386 TKNYGKTILT396 KEADLVTTHE406 LGHNFGAEHD416 PDGLAECAPN 426 EDQGGKYVMY436 PIAVSGDHEN446 NKMFSQCSKQ456 SIYKTIESKA466 QECFQERSN |
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .IH6 or .IH62 or .IH63 or :3IH6;style chemicals stick;color identity;select .A:346 or .A:347 or .A:348 or .A:349 or .A:350 or .A:351 or .A:398 or .A:401 or .A:402 or .A:405 or .A:406 or .A:409 or .A:415 or .A:434 or .A:436 or .A:437 or .A:438 or .A:439 or .A:440; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| Ligand Name: 3-{[4-(But-2-Yn-1-Yloxy)phenyl]sulfonyl}propane-1-Thiol | Ligand Info | |||||
| Structure Description | Novel thio-based TACE inhibitors Part 2: Rational design, synthesis and SAR of thiol-contaning aryl sufones | PDB:3B92 | ||||
| Method | X-ray diffraction | Resolution | 2.00 Å | Mutation | Yes | [10] |
| PDB Sequence |
ADPDPMKNTC
225 KLLVVADHRF235 YRYMGRGEES245 TTTNYLIELI255 DRVDDIYRNT265 AWDNAGFKGY 275 GIQIEQIRIL285 KSPQEVKPGE295 KHYNMAKSYP305 NEEKDAWDVK315 MLLEQFSFDI 325 AEEASKVCLA335 HLFTYQDFDM345 GTLGLAYVGS355 PRANSHGGVC365 PKAYYSPVGK 375 KNIYLNSGLT385 STKNYGKTIL395 TKEADLVTTH405 ELGHNFGAEH415 DPDGLAECAP 425 NEDQGGKYVM435 YPIAVSGDHE445 NNKMFSQCSK455 QSIYKTIESK465 AQECFQERS |
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .440 or .4402 or .4403 or :3440;style chemicals stick;color identity;select .A:346 or .A:347 or .A:348 or .A:349 or .A:350 or .A:351 or .A:398 or .A:401 or .A:402 or .A:405 or .A:406 or .A:409 or .A:415 or .A:434 or .A:436 or .A:437 or .A:438 or .A:439 or .A:440; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| Ligand Name: N-{(2r)-2-[2-(Hydroxyamino)-2-Oxoethyl]-4-Methylpentanoyl}-3-Methyl-L-Valyl-N-(2-Aminoethyl)-L-Alaninamide | Ligand Info | |||||
| Structure Description | Crystal structure of TACE in complex with TAPI-2 | PDB:2DDF | ||||
| Method | X-ray diffraction | Resolution | 1.70 Å | Mutation | Yes | [11] |
| PDB Sequence |
PDPMKNTCKL
227 LVVADHRFYR237 YMGRGEESTT247 TNYLIELIDR257 VDDIYRNTAW267 DNAGFKGYGI 277 QIEQIRILKS287 PQEVKPGEKH297 YNMAKSYPNE307 EKDAWDVKML317 LEQFSFDIAE 327 EASKVCLAHL337 FTYQDFDMGT347 LGLAYGGSPH361 GGVCPKAYYS371 PVGKKNIYLN 381 SGLTSTKNYG391 KTILTKEADL401 VTTHELGHNF411 GAEHDPDGLA421 ECAPNEDQGG 431 KYVMYPIAVS441 GDHENNKMFS451 QCSKQSIYKT461 IESKAQECFQ471 ERS |
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .INN or .INN2 or .INN3 or :3INN;style chemicals stick;color identity;select .A:345 or .A:346 or .A:347 or .A:348 or .A:349 or .A:350 or .A:351 or .A:389 or .A:390 or .A:401 or .A:402 or .A:405 or .A:406 or .A:409 or .A:415 or .A:436 or .A:437 or .A:438 or .A:439 or .A:440; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
MET345
3.333
GLY346
2.988
THR347
3.345
LEU348
2.853
GLY349
3.260
LEU350
4.240
ALA351
4.584
ASN389
3.476
TYR390
2.716
LEU401
4.572
|
|||||
| Click to View More Binding Site Information of This Target and Ligand Pair | ||||||
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | IK682, a tight binding inhibitor of TACE. Arch Biochem Biophys. 2006 Jul 1;451(1):43-50. | ||||
| REF 2 | Synthesis and activity of tryptophan sulfonamide derivatives as novel non-hydroxamate TNF-alpha converting enzyme (TACE) inhibitors. Bioorg Med Chem. 2009 Jun 1;17(11):3857-65. | ||||
| REF 3 | Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket. Bioorg Med Chem Lett. 2008 Nov 1;18(21):5809-14. | ||||
| REF 4 | Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9. | ||||
| REF 5 | Discovery and SAR of hydantoin TACE inhibitors. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1877-80. | ||||
| REF 6 | Biaryl substituted hydantoin compounds as TACE inhibitors. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5286-9. | ||||
| REF 7 | Structure and activity relationships of tartrate-based TACE inhibitors. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4812-5. | ||||
| REF 8 | Novel thiol-based TACE inhibitors: rational design, synthesis, and SAR of thiol-containing aryl sulfonamides. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2250-3. | ||||
| REF 9 | Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates. Bioorg Med Chem Lett. 2005 Oct 1;15(19):4345-9. | ||||
| REF 10 | Novel thiol-based TACE inhibitors. Part 2: Rational design, synthesis, and SAR of thiol-containing aryl sulfones. Bioorg Med Chem Lett. 2008 Jan 1;18(1):44-8. | ||||
| REF 11 | Stabilization of the autoproteolysis of TNF-alpha converting enzyme (TACE) results in a novel crystal form suitable for structure-based drug design studies. Protein Eng Des Sel. 2006 Apr;19(4):155-61. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.